klein-putz.net

Hallo,

weiß jemand, ob man durch DHEA die Eizellreifung verbessern kann?

LG Terra

Ich hatte das DHEA und es hat meine Eizellqualität sehr verbessert.
Das Problem war aber dann die Einnistung!

Hallo,
zu DHEA habe ich hier ja schon mehrfach geschrieben. Immer mehr Studien mit pos. Ergebnissen werden veröffentlicht.
Googeln Sie mal: Norbert Gleicher und Sönmezer und DHEA.
Peet

Barad, D., Gleicher, N., 2005. Increased oocyte production after
treatment with dehydroepiandrosterone. Fertil. Steril. 84, 756.
Barad, D., Gleicher, N., 2006. Effect of dehydroepiandrosterone on
oocytes and embryo yields, embryo grade and cell number in
IVF. Hum. Reprod. 21, 2845–2849.
Barad, D.H., Weghofer, A., Gleicher, N., 2007a. Age-specific levels
of basal follicle stimulating hormone assessment of ovarian
function. Obstet. Gynecol. 109, 1404–1410.
Barad, D., Brill, H., Gleicher, N., 2007b. Update on the use of
dehydroepiandrosterone supplementation among women with
diminished ovarian function. J. Assist. Reprod. Genet. 24, 629–
634.
Barad, D.H., Weghofer, A., Gleicher, N., 2009a. Comparing anti-
Mu¨llerian hormone (AMH) and follicle-stimulating hormone (FSH)
a predictors of ovarian function. Fertil. Steril. 91, 1553–1555.
Barad, D.H., Weghofer, A., Gleicher, N., 2009b. How predictive of
basic pregnancy potential are extremely low levels of anti-
Mu¨llerian hormone (AMH)? Fertil. Steril. (Suppl.), S178–S179.

M So¨ nmezer1,2,5, B O¨ zmen1,2, AP C¸ il3, S O¨ zkavukcu1,2, T Tascı2, H Olmus4, CS Atabekog˘ lu1,2
1Ankara University School of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey; 2Ankara University
Centre for Research on Human Reproduction, Ankara, Turkey; 3Kirikkale University School of Medicine, Department
of Obstetrics and Gynecology, Kirikkale, Ankara, Turkey; 4Gazi University, Faculty of Science and Art, Department of
Statistics, Ankara, Turkey
5Correspondence: e-mail: msonmezer@gmail.com
Abstract
The effect of dehydroepiandrosterone (DHEA) supplementation on cycle outcome was assessed in patients with poor
ovarian response. In total, 19 poor responder patients who were scheduled to undergo a second intracytoplasmic
sperm injection (ICSI)/embryo transfer cycle were enrolled and first ICSI/embryo transfer cycles were taken as
the control group. All subjects were given DHEA supplementation (25 mg t.i.d.) for at least 3 months prior to their
second ICSI/embryo transfer cycle. In both cycles a fixed dose of rFSH (300 IU/day) and human menopausal gonadotrophin
(HMG) (75 or 150 IU/day) along with a flexible gonadotrophin-releasing hormone (GnRH) antagonist
protocol were administered. A favourable decrease was noted in mean day 3 serum oestradiol concentrations after
DHEA supplementation (75.14 ± 28.93 versus 43.07 ± 11.77; P < 0.01). Increased number of >17 mm follicles
(3 ± 0.7 versus 1.9 ± 1.3; P < 0.05), MII oocytes (4 ± 1.8 versus 2.1 ± 1.8; P < 0.05), top quality day 2 (2.2 ± 0.8 versus
1.3 ± 1.1; P < 0.05) and day 3 embryos (1.9 ± 0.8 versus 0.7 ± 0.6; P < 0.05) were achieved in DHEA-supplemented
cycles. Cycle cancellation rates were reduced (5.3% versus 42.1%; P < 0.01), and the pregnancy rate per
patient and clinical pregnancy rate per embryo transfer (47.4% versus 10.5%; P < 0.01 and 44.4% versus 0%;
P < 0.01) were improved after DHEA supplementation. DHEA supplementation might enhance ovarian response,
reduce cycle cancellation rates and increase embryo quality in poor responders.